<DOC>
	<DOCNO>NCT00898326</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient prostate cancer receive implant radiation therapy luteinizing hormone-releasing hormone agonist may help doctor identify biomarkers related cancer help doctor predict patient respond treatment . PURPOSE : This laboratory study look PSA level biopsy sample undergo implant radiation therapy luteinizing hormone-releasing hormone agonist therapy patient stage I stage II prostate cancer .</brief_summary>
	<brief_title>PSA Levels Biopsy Samples After Implant Radiation Hormone Therapy Patients With Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To analyze biopsy result 36 month permanent iodine I 125 implantation therapy luteinizing hormone-releasing hormone ( LHRH ) agonist therapy patient untreated intermediate-risk prostate cancer . OUTLINE : Patients receive luteinizing hormone releasing-hormone ( LHRH ) agonist therapy permanent iodine I 125 implantation protocol JUSMH-BRI-GU05-01 . Patients undergo blood sample collection tissue biopsy biomarker/laboratory analysis 36 month receive brachytherapy releasing-hormone agonist therapy . PSA level biopsy result compare .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm prostate cancer Previously untreated disease prior participation protocol JUSMHBRIGU0501 Intermediaterisk disease define follow : Clinical stage &lt; T2c Prostatespecific antigen ( PSA ) ≤ 20 ng/mL Gleason score &lt; 8 Previously enrol protocol JUSMHBRIGU0501 PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 3 month WBC ≥ 2,000/μL Hemoglobin ≥ 10.0 g/dL Platelet count ≥ 100,000/μL Serum creatine level ≤ 2.0 mg/dL ALT AST ≤ 100 IU/L No cancer require treatment No poorly control hypertension ( i.e. , diastolic blood pressure ≥ 120 mm Hg ) No severe psychiatric disorder , include schizophrenia dementia No poorly control diabetes Considered appropriate study participation , determine Principal Investigator Clinical Investigator PRIOR CONCURRENT THERAPY : No prior drug benign prostatic hyperplasia ( antiandrogen therapy ) No prior surgery prostate cancer No concurrent steroid drug ( except ointment ) No concurrent antiandrogen therapy</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>